| アブストラクト | OBJECTIVES: Determine the prevaccination healthcare impact of COVID-19 in patients with systemic lupus erythematosus (SLE) in England. DESIGN: Retrospective cohort study of adult patients with SLE from 1 May to 31 October 2020. SETTING: Clinical Practice Research Datalink (CPRD) Aurum and Hospital Episode Statistics (HES) databases from general practitioners across England combining primary care and other health-related data. PARTICIPANTS: Overall, 6145 adults with confirmed SLE diagnosis >/=1 year prior to 1 May 2020 were included. Most patients were women (91.0%), white (67.1%), and diagnosed with SLE at age <50 (70.8%). Patients were excluded if they had a COVID-19 diagnosis before 1 May 2020. PRIMARY AND SECONDARY OUTCOME MEASURES: Demographics and clinical characteristics were compared. COVID-19 severity was determined by patient care required and procedure/diagnosis codes. COVID-19 cumulative incidence, hospitalisation rates, lengths of stay and mortality rates were determined and stratified by SLE and COVID-19 severity. RESULTS: Of 6145 patients, 3927 had mild, 1288 moderate and 930 severe SLE at baseline. The majority of patients with moderate to severe SLE were on oral corticosteroids and antimalarial treatments. Overall, 54/6145 (0.88%) patients with SLE acquired and were diagnosed with COVID-19, with 45 classified as mild, 6 moderate and 3 severe COVID-19. Cumulative incidence was higher in patients with severe SLE (1.4%) compared with patients classified as mild (0.8%) or moderate (0.8%). Ten COVID-19-specific hospital admissions occurred (n=6 moderate; n=4 severe). Regardless of COVID-19 status, hospital admission rates and length of stay increased with SLE severity. Of 54 patients with SLE diagnosed with COVID-19, 1 (1.9%) COVID-19-related death was recorded in a patient with both severe SLE and severe COVID-19. CONCLUSIONS: SLE severity did not appear to impact COVID-19 outcomes in this study. The COVID-19 pandemic is evolving and follow-up studies are needed to understand the relationship between COVID-19 and SLE. |
|---|
| 投稿者 | Rabe, Adrian Paul J; Loke, Wei Jie; Kalyani, Rubana N; Tummala, Raj; Stirnadel-Farrant, Heide A; Were, John; Winthrop, Kevin L |
|---|
| 組織名 | BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK a.rabe@imperial.ac.uk.;Primary Care and Public Health, Imperial College London, London, UK.;East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage,;Hertfordshire, UK.;BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USA.;Oncology Business Unit, Global Medical Affairs, AstraZeneca, Cambridge, UK.;Research Department, Health iQ Limited, London, UK.;Department of Infectious Diseases, Oregon Health & Science University, Portland,;Oregon, USA. |
|---|
